Uncategorized Archives - Page 5 of 148

MondayOct 13, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026

The closing of the public offering provides the company with critical financial flexibility as it continues to advance its pipeline of products. The $7.5 million raised through the public offering is particularly significant in the context of Soligenix’s ongoing clinical development programs. SNGX notes multiple potential value drivers over the next 18 months, including clinical milestones, regulatory interactions and data readouts across its pipeline. Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline (https://ibn.fm/tCsub). This funding extends Soligenix’s cash runway through the end of 2026, ensuring…

FridayOct 10, 2025 11:15 am

Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development

Lantern’s RADR(R) AI platform is helping identify optimal indications and pathways for precision cancer therapies. Dr. Schalop reflects on lessons from developing ONC201, approved for H3K27M-mutant glioma, after a 16-year journey. Both leaders highlight the potential for AI to accelerate regulatory reviews and clinical trial design. The conversation underscores how AI could reduce oncology drug timelines and costs, improving patient access to new treatments, and how STAR-001, Lantern’s new CNS cancer drug, can benefit from these AI-driven insights. In oncology, the path from molecule discovery to patient treatment often stretches over a decade and can consume hundreds of millions of…

ThursdayOct 09, 2025 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL

The expansion of Soligenix’s European Medical Advisory Board underscores the company's commitment to delivering innovative treatment options to European patients. HyBryte (synthetic hypericin) is a first-in-class, photodynamic therapy using synthetic hypericin as a photosensitizer. The company’s efforts could establish HyBryte as a new standard of care for patients who currently have limited options. Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people (https://ibn.fm/ANk8X). Despite its rarity, CTCL presents a substantial…

WednesdayOct 08, 2025 11:15 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT

Izotropic Corp. marks a significant milestone in breast imaging with its patent-pending personalized radiation dose feature with the IzoView Breast CT system Recently, the company secured a $375,000 non-brokered private placement to help with core operations in addition to engaging new PR partners for improved investor communications With projections for global breast imaging expected to hit $8.69 billion by 2030, the company is poised to strategically dominate the market Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a leading medical device firm in the field of breast cancer imaging solutions, is speeding up its efforts towards commercializing its innovations. Izotropic recently…

WednesdayOct 08, 2025 10:30 am

Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability

Oncotelic Therapeutics developed the Deciparticles(TM) technology to improve the bioavailability of drugs, largely thanks to the creation of sub-20nm size of the nanoparticles Sapu Nano, part of Oncotelic’s GMP Bio joint venture, receives clearance to begin Phase 1 trial of Sapu003, an injectable form of Everolimus (Afinitor(R)) for breast cancer In preclinical studies, Sapu003 could raise the bioavailability of Everolimus (Afinitor(R)) from around 10%, as oral pill, up to anywhere from 80 to 100%, as injectable Result hopes for higher bioavailability in that drugs may have dramatically better, faster, and more consistent efficacy for patients Oncotelic Therapeutics (OTCQB: OTLC) is a…

TuesdayOct 07, 2025 10:30 am

HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study

HeartBeam is developing a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems. The VALID-ECG study results carry significant weight for both clinical adoption and HeartBeam’s commercialization pathway. Early and accurate detection of heart rhythm problems can mean the difference between life-saving intervention and a missed opportunity, which is why new advances in cardiac diagnostics carry such weight. HeartBeam (NASDAQ: BEAT) has reported promising results…

TuesdayOct 07, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision enables re-filing of an Abbreviated New Drug Application (“ANDA”) for the company’s KETAFREE(TM) product, which the company has now done. Current ketamine formulations use multidose vials with a toxic preservative, Benzethonium Chloride. U.S. ketamine market is estimated at $750 million annually, presenting a significant commercial opportunity. NRx is also advancing NRX-100 and NRX-101 for suicidal depression and PTSD, both with FDA designations. The move aligns with U.S. policy goals on reshoring drug production and reducing toxic additives. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company,…

WednesdayOct 01, 2025 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment

Sapu Nano received approval from Australia’s Human Research Ethics Committee (“HREC”) to start enrolling patients in clinical trials for Sapu003 Sapu003 uses Sapu Nano’s Deciparticle(TM) technology to deliver more of the Everolimus drug into the bloodstream, which could be more effective than taking the drug in pill form Sapu Nano is a part of a family of companies formed through GMP Biotechnology Limited, which itself is a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic…

WednesdayOct 01, 2025 9:00 am

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development

Hoth Therapeutics (NASDAQ: HOTH) is using Lantern Pharma’s (NASDAQ: LTRN) PredictBBB.ai(TM) platform to accelerate development timelines, reduce risk, and improve candidate selection. This technology helps determine whether or not a candidate is able to cross the blood-brain barrier or not, which is a major holdup for many drug development companies. Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the collaboration and how it can help deliver life-changing therapies for patients. Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company…

TuesdaySep 30, 2025 10:30 am

FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy

Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs A recent Type C meeting with the U.S. Food and Drug Administration provided the company with guidance in working through the regulatory pathway and designing the trial for its investigational therapy LP-184/STAR-001, which will seek a means of battling pediatric brain cancers Lantern Pharma is also using drug candidates in trials to combat glioblastoma (“GBM”), triple-negative breast cancer, non-small cell lung cancer in non-smokers, non-Hodgkin’s lymphoma, and…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026

Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development

Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT

Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability

HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development

FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search